Where the Street stands
These are third-party analyst opinions from named firms, not advice, and not a prediction. Earnings land in 3 days, which usually moves targets. How we score this
20 firms currently rating it, weighted by track record.
The 19 firms with a track record here beat the S&P 41% of the time over 12 months.
Pro: see the crowd-vs-sharp split for ABBVAnalysts rate AbbVie a consensus Buy, with 24 of 28 analysts assigning buy-or-stronger ratings; the average price target of $267.79 implies 4.2% upside from current levels. Most recent actions maintained existing positions across firms: Canaccord Genuity kept a Buy on July 22, while Citigroup and UBS held Neutral ratings in mid-July. The stock trades at a trailing P/E of 126.56 but a forward P/E of 15.77, reflecting a significant expected earnings rebound after EPS declined 46.2% year-over-year, though revenue grew 12.4% and gross margins stand at 72.03%. With a beta of 0.28, ABBV exhibits low volatility relative to the broader market.
Generated from the data on this page; may contain errors. Analyst opinions belong to the named firms. Informational only, not investment advice.
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jul 22, 2026 | Canaccord Genuity | ○ Maintained | |
| Jul 15, 2026 | Citigroup | ○ Maintained |
Create a free account to unlock all analyst ratings, key stats, and news. No credit card, takes 30 seconds.
Sign up free